Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Operating Activities:
Net loss	$ (17,340)	$ (16,598)
Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities:
Depreciation	802	570
Amortization of intangible assets	2,867	2,564
Stock-based compensation	1,786	1,923
Deferred tax benefit	(38)	(697)
Write down of inventory	122	0
Change in fair value of warrant liabilities	1,981	155
Change in fair value of contingent consideration	257	1,056
Changes in operating assets and liabilities:
Accounts receivable	(1,608)	(340)
Inventories	(162)	(1,063)
Other current and long term assets	(21)	(76)
Accounts payable	242	509
Accrued expenses	(2,290)	(433)
Deferred revenue	128	83
Noncurrent operating lease liabilities	3,037	(130)
Net cash and cash equivalents used in operating activities	(10,237)	(12,477)
Investing Activities:
Purchase of property and equipment	(395)	(2)
Net cash and cash equivalents used in investing activities	(395)	(2)
Financing Activities:
Proceeds from issuance of common stock, preferred stock and warrants under 2020 financing, net of issuance costs	0	13,525
Proceeds from issuance of common stock, net of issuance costs	129,322	11,212
Taxes paid related to net share settlement of vesting of restricted stock units	(214)	(33)
Proceeds from exercise of stock options and warrants	30,497	0
Net cash and cash equivalents provided by financing activities	159,605	24,704
Effect of exchange rate changes on cash and cash equivalents	(108)	(51)
Net increase in cash, cash equivalents and restricted cash	148,865	12,174
Cash, cash equivalents and restricted cash, beginning of period	17,529	10,567	$ 10,567
Cash, cash equivalents and restricted cash, end of period	166,394	22,741	$ 17,529
Supplemental Schedule of Non-cash Investing and Financing Activities:
Transfer of inventories to property and equipment	0	1,958
Acquisition of property and equipment in accounts payable	191	0
Reclass of warrant liability to common stock and additional paid-in-capital	2,236	0
Lease liabilities arising from obtaining right-of-use assets	3,427	0
Exchange of common stock for Series B Warrants	0	2,470
Transfer of in-process research and development to intellectual property	0	2,425
Conversion of preferred stock to common stock	$ 0	$ 30